Fisher-Price Recalls Millions Of Rock ‘n Play Sleepers Following Dozens of Infant Deaths

As a result of design problems that have resulted in at least 32 infant deaths, nearly 5 million Fisher-Price Rock‘n Play Sleepers are being recalled, due to a risk that babies may suffocate after becoming trapped against the fabric if they roll over.

The U.S. Consumer Product Safety Commission (CPSC) announced the Fisher-Price Rock’n Play Sleepers recall on April 12, days after the agency issued a warning that urged consumers to stop placing infants in the sleepers before they begin go show signs that they can roll over independently, and to completely stop use of the sleepers by the time an infant is three months old.

The infant deaths appear to have occurred when infants rolled from their back to their stomach while in the sleepers, which are marketed under the “Rock’n Play” brand. The impacted sleepers are inclining, which are similar to bassinets, however they are designed to elevate the baby’s head and torso to help prevent acid-reflux or congestion while sleeping.

Hair-Dye-Cancer-Lawsuits
Hair-Dye-Cancer-Lawsuits

The Rock’n Play models include restraints to prevent an infant from being able to sit up or roll over. However, when a child is not fastened properly in the restraints, the infant may turn on their side, or roll completely over and not have the proper neck strength to lift their head, creating a suffocation risk.

Shortly after the initial CPSC warning was released last week, the American Academy of Pediatrics (AAP) issued a statement on April 9, calling for the commission to issue an immediate recall for the Rock’n Play Sleepers. The AAP determined the inclined sleepers are unsafe and that the CPSC warning did not go far enough to ensure the safety of infants.

“When parents purchase a product for their baby or child, many assume that if it’s being sold in a store, it must be safe to use,” AAP President Dr. Kyle Yasuda said in the statement. “Tragically, that is not the case. There is convincing evidence that the Rock ‘n Play inclined sleeper puts infants’ lives at risk, and CPSC must step up and take immediate action to remove it from stores and prevent further tragedies.”

Following the AAP’s statement, Fisher-Price voluntarily announced the recall under the CPSC’s Fast Track recall process.

The recall affects approximately 4.7 million Rock’n Play Sleepers manufactured in China under Fisher-Price, of East Aurora, New York. They were distributed for sale throughout the United States to major retailers for between $40 and $149 since 2009. The recall involves all Rock’n Play models.

The CPSC instructs consumers to stop using the sleepers immediately and to contact Fisher-Price at 866-812-6518 or visit them online to view the Recalls & Safety Alerts for information on how to receive a refund or voucher.

According to the FDA, about 4,000 infants annually die unexpectedly during sleep from accidental suffocation, sudden infant death syndrome, or unknown causes. Many of the reported fatalities are a result of suffocation from rolling on their sides or stomach.

To reduce suffocation and accidental deaths, the AAP recommends infants sleep on their backs positioned on a firm, empty surface, not containing any soft objects toys, pillows or loose bedding. The recommendation for new parents is to always follow the ABCs of safe sleep: Alone on the Back in a bare Crib.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025.
Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case.
An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe.